Company Overview - Biodesix is a leading diagnostics company focused on improving clinical care and patient outcomes[1, 12] - The company's mission is to transform patient care through personalized diagnostics that are timely, accessible, and address immediate clinical needs[13] - Biodesix envisions a world where patient diseases are conquered with the guidance of personalized diagnostics[14] Business Lines and Key Capabilities - Biodesix generates revenue through two business lines: Lung Diagnostic Tests and Development Services[15] - The company expects to have approximately 95 sales representatives focused on lung diagnostics in the field by 4Q25[19] - Biodesix boasts industry-leading gross margins of 794%[19] - Development Services had $109 million in contracts not yet recognized as of the end of Q1 2025[73] Lung Diagnostic Tests - Lung cancer accounts for approximately 1 in 5 cancer deaths annually in the USA[29] - Approximately 80% of patients assessed for lung cancer risk fall into the low to moderate risk category (5-65%)[37, 43] - The Nodify Lung test identifies likely malignant nodules with 78% PPV, 98% specificity, and 28% sensitivity, and identifies likely benign nodules with 98% NPV, 97% sensitivity, and 44% specificity[46] Financial Performance - Total revenue for Q1 2025 was $180 million, representing a 21% year-over-year growth[76, 78] - Lung Diagnostics revenue in Q1 2025 was $163 million, an 18% increase year-over-year[76, 81] - Development Services revenue in Q1 2025 was $17 million, a 61% increase year-over-year[76, 81]

Financial Position & Pipeline - Cytokinetics had approximately $1.1 billion in cash, cash equivalents, and investments as of March 31, 2025[9] - Cytokinetics has further access to capital, including up to $275 million in term loan facilities with Royalty Pharma[176] - Royalty Pharma has the option to invest up to $150 million in a Phase 3 trial of CK-586 in exchange for an additional 3.5% revenue participation interest in worldwide net sales of CK-586[9, 176] - 2025 GAAP operating expense is guided to be between $670 million and $710 million, including $110 million to $120 million in stock-based compensation[178] Aficamten Program - The U S PDUFA date for aficamten is December 26, 2025, with China NDA and EU MAA on file[8, 92, 181] - Positive topline results from MAPLE-HCM demonstrated superiority of aficamten to metoprolol in patients with obstructive HCM[96, 99, 181] - SEQUOIA-HCM pivotal Phase 3 trial enrolled 282 patients with oHCM treated with standard of care[42] - SEQUOIA-HCM showed a statistically significant improvement in exercise capacity compared to placebo, with a least squares mean difference of 1 74 mL/kg/min (p=0 000002)[46, 47] - In the SEQUOIA-HCM CMR sub-study, aficamten was associated with a significant improvement in Left Ventricular Mass Index (LVMI) of -15 4 g/m2 (p=0 001)[62, 63] Omecamtiv Mecarbil Program - COMET-HF is a Phase 3 confirmatory clinical trial for omecamtiv mecarbil[128, 181] - The COMET-HF trial is targeting a patient population of approximately 840,000 high-risk heart failure patients with EF<30% in the US[21, 133] CK-586 Program - AMBER-HFpEF is a Phase 2 clinical trial evaluating CK-586 in HFpEF patients with LVEF ≥ 60%[163, 166] - Approximately 84% of HFpEF patients will die within five years of initial hospitalization[143, 144]

Business Overview and Strategy - Power Integrations (PI) is the only high-voltage (HV) pure play semiconductor company[11, 33, 55, 68] - The company focuses on system-level solutions for high-voltage power conversion, leveraging proprietary technologies and extensive IP protection[12, 13] - PI's unique "Fabless IDM" manufacturing model ensures best-in-class supply, quality, and cost[31] Market and Growth Opportunities - PI's addressable market is expanding and diversifying, projected to double from 2022 to 2027, reaching $8 billion[11, 33, 36, 38, 109] - The company's revenue mix is shifting towards industrial, automotive, and appliance sectors, which accounted for over 70% of the mix[108] - GaN (Gallium Nitride) is identified as the future of HV power conversion, and PI is a leader in GaN technology[11, 33, 56, 68] Financial Performance and Sustainability - 52% of 2024 sales came from product families introduced in 2001 and prior, demonstrating annuity revenue streams from long-lived products[29] - The company targets a low-double-digit CAGR (Compound Annual Growth Rate) for revenue growth and aims for a non-GAAP gross margin of 50-55% and a non-GAAP operating margin of 25-30%[109] - In 2024, 95% of Power Integrations' revenues were EU Taxonomy-Eligible[74] - EcoSmart technology saved an estimated 11.5 TWh of standby energy in 2024[77] - Free cash flow was 15% of revenue in 2024, and 185% of free cash flow was returned to stockholders between 2022 and 2024[113]

Financial Performance - Net interest margin improved to 267% for Q3 2024 compared to 262% for Q2 2024[14,19] - Return on average assets increased to 077% for Q3 2024 compared to 059% for Q2 2024[19] - Core return on average assets increased to 063% for Q3 2024 compared to 052% for Q2 2024[19] - Net income was $5381 thousand for Q3 2024[18,38] Balance Sheet Optimization and Capital Management - Outstanding borrowings under the BTFP decreased by $1200 million to $1090 million at September 30 2024 compared to $2290 million at June 30 2024[14] - Total loans decreased by $109 million or 05% to $216 billion at September 30 2024 compared to $217 billion at June 30 2024[19,64] - The company repurchased 2000 shares during Q3 at an average price of $1850 per share[14] - Total deposits increased $772 million or 35% to $229 billion at September 30 2024 compared to $221 billion at June 30 2024[91] Asset Quality - Nonperforming assets to total assets was 032% at September 30 2024 compared to 030% at June 30 2024[14] - The allowance for credit losses to nonperforming loans was 6820% at September 30 2024 compared to 5764% at June 30 2024[14] - Nonperforming loans improved to 019% of total loans at September 30 2024 compared to 023% at June 30 2024[19]

Financial Performance & Capital Management - Investar Holding Corporation's regulatory common equity tier 1 capital ratio increased to 1085% at December 31, 2024, compared to 951% at December 31, 2023[19] - Book value per common share increased to $2455, or 55%, at December 31, 2024, compared to $2326 at December 31, 2023[19] - Tangible book value per common share increased to $2031, or 73%, at December 31, 2024, compared to $1892 at December 31, 2023[19] - Return on average assets increased to 088% for the fourth quarter of 2024, compared to 077% for the third quarter of 2024[24] - Core return on average assets increased to 093% for the fourth quarter of 2024, compared to 063% for the third quarter of 2024[24] Balance Sheet Optimization & Loan Portfolio - Variable-rate loans as a percentage of total loans was 32% at December 31, 2024[20, 23] - The consumer mortgage portfolio decreased $47 million, or 19%, to $2425 million at December 31, 2024, compared to $2472 million at September 30, 2024[23] - Total loans decreased $308 million, or 14%, to $213 billion at December 31, 2024, compared to $216 billion at September 30, 2024[24, 68] Expense Control & Efficiency - GAAP noninterest expense increased by $04 million, or less than 1%, to $630 million for 2024 compared to $626 million for 2023[19] - Core noninterest expense increased by $10 million, or 17%, to $628 million for 2024 compared to $618 million for 2023[19] - Efficiency ratio improved to 7100% for the fourth quarter of 2024, compared to 7561% for the third quarter of 2024[24]

Financial Performance - In 2024, annuity sales reached $178 billion, with AUM (Assets Under Management) at $325 billion[8] - Free capital generation for 2024 was $13 billion, and capital return was $631 million[8] - For the first quarter of 2025, the net loss attributable to Jackson Financial Inc common shareholders was $35 million, or $048 per share[15, 16] - Adjusted Operating Earnings for 1Q25 was $376 million, or $510 per share[15, 16] - Retail annuity sales for 1Q25 totaled $40 billion, a 9% increase over the prior year[16] - Consolidated Pretax Adjusted Operating Earnings for 1Q25 was $442 million, while Retail Annuity Pretax Adjusted Operating Earnings was $420 million[16] Capital Management - Cash distributed to JFI increased significantly from $45 million in 1Q24 to $240 million in 1Q25[19] - Free cash flow increased from $20 million in 1Q24 to $213 million in 1Q25[19] - Capital returned to common shareholders increased from $172 million in 1Q24 to $231 million in 1Q25[21] - JNLIC's estimated RBC ratio was 585% as of the end of 1Q25, after reflecting $240 million of distributions from JNLIC to JFI[26]

Financial Performance & Guidance - CooperCompanies' FY24 revenue reached $3.9 billion[6] - The company anticipates FY25 total revenue between $4.107 billion and $4.146 billion[10] - CooperVision's FY24 revenue was $2.6 billion[18], with FY25 guidance between $2.759 billion and $2.786 billion[10] - CooperSurgical's FY24 revenue was $1.29 billion[22], with FY25 guidance between $1.347 billion and $1.359 billion[10] - CooperCompanies projects organic growth of 5%-6% for FY25[10] Market Position & Growth - The global soft contact lens market is an $11 billion market[12] - CooperVision holds 26% of the contact lens market share[13] - The fertility market is estimated to be over $2 billion globally[27] and has historically grown at 5-10% annually[27] - CooperSurgical has grown through 40+ acquisitions since 1990[24] Business Segments - Toric and multifocal lenses account for 48% of CooperVision's revenue[18] - Fertility products and services comprise 40% of CooperSurgical's revenue, while office and surgical products make up 60%[22]

Financial Performance & Targets - UGI Corporation's YTD FY25 GAAP diluted EPS is $3.93, compared to $2.74 in YTD FY24[39] - The company increased its Fiscal 2025 adjusted EPS guidance to a range of $3.00 - $3.15 per share[39] - The company targets a long-term EPS growth rate of 4-6%[18] - The company targets a rate base growth of 9%+[18] - The company's leverage ratio target is between 3.5 – 4.0x[23] Capital Allocation & Deployment - The company plans to deploy approximately $3.9 billion in capital from FY24-27[25] - Approximately 66% of the capital will be returned to shareholders[25] - Approximately 18% of the capital will be used for debt reduction[25] - Approximately 85% of total capital invested in natural gas businesses[26] ESG - The company targets a 55% reduction in 5-year Scope-1 GHG Emissions[31]

Rexford Industrial Overview - Rexford Industrial Realty has a portfolio of 424 industrial properties, encompassing 51 million square feet, with an entity value of $13 billion[7] - The company focuses on prime infill locations in Southern California[7, 13] - Rexford's FFO per share growth has a 5-year CAGR of 10%, exceeding the REIT average of 3%[9, 10] - The dividend per share growth has a 5-year CAGR of 16%, significantly higher than the REIT average of 3%[9, 10] Growth and Value Creation - Rexford has substantial embedded cash NOI growth, including a $60 million portfolio mark-to-market, $105 million in annual embedded rent steps, and $70 million from repositioning and redevelopment[17] - Repositioning and redevelopment projects in-process or in lease-up are expected to generate $70 million in annualized stabilized cash NOI[17, 18, 25] - The company's leasing activity in 1Q 2025 covered 2.4 million square feet, with average embedded rent steps of 3.6% in executed leases[28] Market and Portfolio - Southern California is the largest and highest-value industrial market in the nation, valued at $32 billion with 2.1 billion square feet[38] - Rexford's portfolio has a trailing 12-month average executed lease rate of $19.16 per square foot, a 22% premium over the Infill SoCal average of $15.65[59] - Over the last 4 years, >85% of transactions were executed off/lightly-marketed[34]

Financial Performance and Guidance - Blue Bird confirms FY25 revenue guidance of $1425 million to $1475 million[45] - The company anticipates an adjusted EBITDA of approximately $200 million with a margin of ~14% for FY25[45, 47] - Q2 FY25 adjusted EBITDA reached $49 million with a 14% margin, marking a $3 million increase compared to Q2 FY24[66, 67, 69] - Adjusted free cash flow for Q2 FY25 was $19 million[66, 69] Industry and Market Position - The school bus industry is expected to reach approximately 31,000 units in FY25[22] - Over 47% of school buses in service are 10 years or older, supporting replacement demand[24] - Blue Bird holds a leading market position in alternative power and electric school buses, with over 60% of sales being non-diesel[31, 34] Strategic Initiatives - Blue Bird is expanding its total addressable market (TAM) through the introduction of an EV commercial chassis offering[15, 40] - The company is focused on reducing structural costs through Lean Transformation initiatives[15] - Blue Bird was awarded an $80 million grant by the DOE for a new plant to support profitable growth plans for 12,000+ units[50, 52]